Prognostic Assessment and Risk Stratification of Laryngeal Spindle Cell Carcinoma: A Multicenter Retrospective Study

  • 0Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

Summary

This summary is machine-generated.

Laryngeal spindle cell carcinoma (LSpCC) shows a worse prognosis than laryngeal squamous cell carcinoma (LSCC). A validated nomogram aids in predicting LSpCC survival, guiding personalized treatment strategies for this aggressive cancer.

Area Of Science

  • Oncology
  • Pathology
  • Medical Statistics

Background

  • Laryngeal spindle cell carcinoma (LSpCC) is a rare and aggressive subtype of laryngeal cancer.
  • Clinicopathological features and prognostic factors for LSpCC require further elucidation.
  • Distinguishing LSpCC from the more common laryngeal squamous cell carcinoma (LSCC) is crucial for appropriate management.

Purpose Of The Study

  • To compare clinicopathological characteristics between LSpCC and LSCC.
  • To develop and validate a prognostic model for predicting overall survival in LSpCC patients.

Main Methods

  • A multicenter retrospective cohort study utilizing data from West China Hospital and the SEER database (2009-2022).
  • Inclusion of 37 LSpCC cases and 432 LSpCC cases, with LSCC patients matched for comparison.
  • Analysis involved Kaplan-Meier curves, Cox regression, and development of a prognostic nomogram, validated internally and externally using AUC, calibration plots, and decision curve analysis (DCA).

Main Results

  • LSpCC patients were predominantly male, with a mean age of 61.03 years.
  • LSpCC demonstrated a significantly poorer prognosis compared to LSCC (P=.043).
  • Key prognostic factors identified for overall survival included age, tumor stage, primary site, and treatment approach. The nomogram achieved strong predictive accuracy (AUC 0.722-0.858).

Conclusions

  • Laryngeal spindle cell carcinoma carries a poor prognosis.
  • A validated prognostic nomogram is now available for individualized survival prediction in LSpCC.
  • Findings emphasize the need for tailored treatment strategies for LSpCC, an aggressive cancer subtype.